Jul 30,2019

DarioHealth Launches New Blood Pressure Monitoring System

DarioHealth announced today the addition of a new digital monitoring solution on its Dario app platform that will allow patients to monitor their blood pressure throughout the day, in addition to their blood glucose levels. The Dario Blood Pressure Monitoring System is a medical device composed of a digital monitor and a blood pressure cuff, that synchronizes with the Dario mobile app which allows users to track their blood pressure and a variety of health markers, along with the daily actions that influence them. Together with Dario's software and professional coaching, we believe that users with hypertension and diabetes will benefit from a clear broad picture of their condition in a user-friendly format on their iPhone or Android mobile device.

PRODUCT

#mobile app

#coaching

#connected device

View Analyst & Ambassador Comments
Go to original news
Mar 19,2019

One Drop Partners With Amazon's Choice To Expand Health Services Offering

One Drop, a leader in the development of digital therapeutics solutions for people with diabetes and related conditions, today announced a partnership with Amazon's exclusive health brand, Choice. Through this partnership, One Drop and Amazon's Choice will bring affordable, accessible, and comprehensive digital health management services to Amazon's Choice customers living with diabetes and hypertension nationwide.

COLLABORATION PARTNERSHIP

#institution

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Apr 10,2019

Study: Behavioral coaching app reduces hypertensive participants' blood pressure

The investigation examined Better Therapeutics’ candidate digital therapeutic for cardiovascular disease, a daily-use app that encourages users to set and record their progress toward individualized behavioral goals. The app is supported by a remote multidisciplinary team that looks to support healthy behavior changes, with users receiving scheduled calls from a health coach over the course of a 12-week program. Among 172 participants with hypertension, 75 percent achieved a “clinically meaningful” improvement in blood pressure. The group was 86 percent women and the mean age in the sample was 55.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
May 22,2019

Better Therapeutics to Present Health Economic Data at ISPOR 2019

Better Therapeutics, a developer of prescription digital therapeutics for the treatment of cardiometabolic diseases, today announced an upcoming poster presentation of health economic data at the ISPOR 2019 Conference May 18 - 22 in New Orleans. The presentation will include data on the reduction of health resource utilization and cost-effectiveness of Better’s digital behavioral intervention in type 2 diabetes and hypertension.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 26,2019

Omada Health Raises $73 Million to Accelerate Program Expansion

Omada Health today announced a $73 million round of funding led by Wellington Management Company LLP. Wellington Management is an independent investment firm with more than $1 trillion of client assets under management. Omada will use the funding to fuel the continued expansion of its digital care program, including support for those with type 2 diabetes and hypertension, as well as those dealing with anxiety and depression.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Aug 15,2019

DarioHealth Announces Alliance with DigitalHealth.London As Part of the UK Israel Dangoor Health Initiative

DarioHealth today announced an alliance with DigitalHealth.London as part of its UK Israel Dangoor Health Initiative, which aims to partner leading Israeli digital health companies with the UK National Health Service (NHS) to benefit patients. Dario was selected by DH.L to help bring its highly regarded digital therapeutics technology to assist NHS patients in better managing their chronic health conditions, such as pre-diabetes, diabetes and hypertension, among other chronic conditions.

COLLABORATION PARTNERSHIP

#institution

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 12,2019

Omada Program Launches Preferred Devices to Monitor Blood Sugar, Blood Pressure

Omada Health today announced the inclusion and integration of FDA-cleared, cellular-connected blood pressure monitors and glucometers for qualifying participants in the company’s chronic condition management program. The integration of these devices will enable individuals to seamlessly upload real-time readings to their Omada account, while providing Omada coaches insight to deliver personalized guidance and ongoing support as participants work to improve their health.

PRODUCT

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 11,2018

Cambia Health Solutions and Livongo Team Up on Chronic Health Conditions

Cambia Health Solutions (Cambia) and Livongo Health (Livongo) today announced a strategic partnership that combines Cambia’s vision to redesign health and health care to be more consumer-driven with Livongo’s proven ‘whole person’ approach to empowering people with chronic conditions to live better and healthier lives. Initially, the companies will work together to make Livongo’s category-leading Livongo for Diabetes solution available to Regence Blue Cross and Blue Shield in Idaho, Oregon, Utah, and Washington. The companies will then expand their partnership to co-develop solutions that personalize care for conditions such as hypertension and integrated behavioral health to improve consumers’ lives nationwide.

COLLABORATION PARTNERSHIP

#insurance

View Analyst & Ambassador Comments
Go to original news
Aug 22,2018

CureApp Inc., developing “Digital Therapeutics ”, starts joint-development and clinical research of Digital Therapeutics for hypertension with Jichi Medical University.

CureApp Inc. announced it starts joint-development and clinical research of "Digital Therapeutics" for hypertension with Professor Kazuomi Kario of Cardiovascular Medicine, Jichi Medical University. The clinical research explores the anti-hypertensive effects of the "Digital Therapeutics" and aims to create a novel treatment strategy for hypertension other than medication.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 30,2018

Voluntis Extends Partnership with AstraZeneca in Digital Therapeutics for Oncology

Voluntis (Paris:VTX), a digital biotech specialized in digital therapeutics, has announced the extension of its collaboration with AstraZeneca (NYSE: AZN) in the field of oncology. As part of the renewed agreement, the partners will implement a new phase of clinical evaluation of their digital therapeutic designed to support platinum resistant ovarian cancer patients treated with a combination of Cediranib plus Olaparib. The eCO (eCediranib/Olaparib) solution will be tested in the GY005 randomized phase III clinical trial sponsored by the National Cancer Institute (NCI), which will evaluate if the digital therapeutic can complement treatment by determining whether it enables better management of side effects and thereby improves patient outcomes.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Subscribe to HYPERTENSION